Abstract 741P
Background
Determination of the molecular subtype of endometrial cancer has been shown to be prognostic and predictive and is therefore essential for treatment decisions and prognosis prediction in endometrial cancer. Therefore, assessment of mismatch repair protein (MMR) deficiency by immunohistochemistry (IHC) and sequential microsatellite instability (MSI) in cases with indeterminate protein expression status is part of routine diagnostics in the diagnosis of endometrial cancer. Several methods are available for MSI analysis.
Methods
We compared the Idylla™ MSI Assay (Biocartis) with our institutional MSI gold standard test (Bethesda panel) and with MMR IHC in a cohort of n=332 hysterectomy specimen of endometrioid adenocarcinomas of the corpus uteri (2008-2016). MSI tests were performed according to the manufacturer's recommendations (Idylla™) and a validated internal protocol (Bethesda panel). MMR IHC was analyzed using tissue microarrays, but repeated on whole slides in case of a negative internal control or a discrepancy with the MSI test. The Idylla™ MSI results were compared with the Bethesda MSI results and the MMR-IHC.
Results
In our cohort of n=332 endometrioid endometrial cancer cases, MMR IHC, Idylla™ MSI and gold standard (Bethesda) MSI test results were evaluable in all cases, n=325, and n=324, respectively. N=87/332 (26.2%) had MMR deficiency (MMRd) with n=78/332 (23.5%) showing MLH1/PMS2 loss. The Idylla™ MSI assay revealed MSI in n=68/325 (20.9%) cases. Idylla™ results agreed with MMR IHC results in n=303/325 cases (overall percentage agreement (OPA)=93.2%; Kappa= 0.814). Bethesda results were consistent with MMR IHC results in n=310/324 cases (OPA=95.7%; Kappa= 0.884). Both Idylla™ and Bethesda MSI results were available for n=322/332 cases (97.0%) with n=308/322 concordant cases. OPA between the two MSI test methods was therefore 95.65% (Kappa= 0.874).
Conclusions
Idylla™ MSI showed a very high OPA with the gold standard MSI test and with MMR IHC. In view of its short turnaround time and ease of use, this test could therefore be an excellent alternative for MSI testing in endometrial cancer, even with old tissue samples.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Biocartis provided the cartridges free of charge.
Disclosure
R. Erber: Financial Interests, Institutional, Research Funding: Biocartis; Financial Interests, Personal, Invited Speaker: AstraZeneca. I. Unser, A. Hartmann, R. Stöhr: Financial Interests, Institutional, Research Funding: Biocartis. All other authors have declared no conflicts of interest.
Resources from the same session
671P - LuMIERE: A phase I/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors
Presenter: Jonathan McConathy
Session: Poster session 01
672P - Inference failure with synthetic arms: Empirical application to phase III oncology trials
Presenter: Alexander Decruyenaere
Session: Poster session 01
673P - Project Optimus for dose optimization: Implementation strategies for your trial from the statistician’s standpoint
Presenter: Miguel Pereira
Session: Poster session 01
674P - Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs
Presenter: Sebastian Albers
Session: Poster session 01
675P - Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer)
Presenter: Lin Shen
Session: Poster session 01
678TiP - A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations
Presenter: Charlotte Lemech
Session: Poster session 01
679TiP - Cancer Research UK phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 as monotherapy and in combination with immunotherapy in patients (pts) with advanced solid tumors
Presenter: Debashis Sarker
Session: Poster session 01
680TiP - A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies
Presenter: Anna Minchom
Session: Poster session 01
681TiP - A phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study of AMXI-5001 in patients with advanced malignancies
Presenter: Lee Rosen
Session: Poster session 01